Newsroom | 8087 results

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la compañía líder en terapias de ARN de interferencia (ARNi), ha anunciado hoy que la Comisión Europea (CE) ha concedido la aprobación para el tratamiento de la amiloidosis de transtiretina común o hereditaria en pacientes adultos con cardiomiopatía (ATTR-CM) como indicación adicional para su terapia huérfana de ARNi AMVUTTRA® (vutrisiran). El comunicado en el idioma original es la versión oficial y autoriz...

CARLSBAD, Calif.--(BUSINESS WIRE)--On June 10, 2025, Austrian ultra-endurance athlete Philipp Kaider will begin his most ambitious challenge yet: the Race Across America (RAAM). Spanning nearly 5,000 kilometers from the Pacific to the Atlantic, RAAM is widely regarded as one of the toughest endurance races in the world—demanding continuous cycling across extreme terrain, weather conditions, and time zones. This marks Kaider’s first attempt at the iconic race, a feat that tests not just physical...

KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc., the leader in artificial intelligence-powered blood tests for cardiovascular disease, today announced that it has been granted patents for its HART CADhs® test in the United States—marking the second U.S. patent for this novel test—as well as the European Union and Japan. These patents protect Prevencio’s proprietary methods and algorithms for detecting obstructive coronary artery disease (CAD) using a multi-protein, AI-driven blood test platfo...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s IP portfolio....

NORTH CHICAGO, Ill.--(BUSINESS WIRE)--32 Biosciences, a leader in the field of gut microbiome medicine, today announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key regulatory milestones. 32 Biosciences’ diagnostic platform technology quantitatively evaluates the gut microbiome’s functional health, assessing its ability to support key bodily functio...

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq : ALNY), la principale société de traitement par ARN interférent (ARNi), annonce aujourd'hui que la Commission européenne (CE) a accordé l'approbation pour le traitement de la cardiomyopathie amyloïde de type sauvage ou transthyrétine héréditaire (ATTR-CM) chez les patients adultes en tant qu'indication supplémentaire pour sa thérapie par ARNi orphelin AMVUTTRA® (vutrisiran). L'approbation élargit l'indication pour...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la società leader nel settore terapeutico dell'interferenza dell'RNA (RNAi), oggi ha annunciato che la Commissione europea (CE) ha concesso l'approvazione per il trattamento dell'amiloidosi da transtiretina di tipo wild o ereditaria in pazienti adulti con cardiomiopatia (ATTR-CM) come indicazione aggiuntiva per il suo farmaco orfano RNAi AMVUTTRA® (vutrisiran). Il testo originale del presente annuncio, redatto nell...

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das führende Unternehmen im Bereich der RNA-Interferenz (RNAi)-Therapeutika, gab heute bekannt, dass die Europäische Kommission (EK) die Zulassung für die Behandlung von Wildtyp- oder hereditären Transthyretin-Amyloidosen bei erwachsenen Patienten mit Kardiomyopathie (ATTR-CM) als zusätzliche Indikation für sein Orphan-RNAi-Therapeutikum AMVUTTRA® (Vutrisiran) erteilt hat. Die Zulassung erweitert die Indika...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), het toonaangevende bedrijf op het gebied van RNA-interferentietherapie (RNAi), kondigde vandaag aan dat de Europese Commissie (EC) een goedkeuring heeft verleend voor de behandeling van wildtype of erfelijke transthyretine amyloïdose bij volwassen patiënten met cardiomyopathie (ATTR-CM) als een aanvullende indicatie voor zijn RNAi-weestherapie AMVUTTRA® (vutrisiran). Deze bekendmaking is officieel geldend in de ori...

HUDSON, Wis.--(BUSINESS WIRE)--Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance...